Erbitux (ImClone Systems Inc)
Erbitux (ImClone Systems Inc) Brand names, Erbitux (ImClone Systems Inc) Analogs
Erbitux (ImClone Systems Inc) Brand Names Mixture
- Actinac Pwr (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
- Actinac Pws (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
- Chlorasone (Chloramphenicol + Prednisolone Acetate)
- Elase Chloromycetin Ont (Chloramphenicol + Deoxyribonuclease Pancreatic + Fibrinolysin)
- Liquichlor (Chloramphenicol + Prednisolone + Squalane + Tetracaine)
- Ophthocort Ont (Chloramphenicol + Hydrocortisone Acetate + Polymyxin B)
- Sopamycetin/Hc Ointment (Chloramphenicol + Hydrocortisone Acetate)
- Sopamycetin/Hc Ont (Chloramphenicol + Hydrocortisone Acetate)
- Sopamycetin/Hc Susp (Chloramphenicol + Hydrocortisone Acetate)
- Zoomycetine Spray (Chloramphenicol + Isopropyl Alcohol + Methyl Violet)
Erbitux (ImClone Systems Inc) Chemical_Formula
C6484H10042N1732O2023S36
Erbitux (ImClone Systems Inc) RX_link
http://www.rxlist.com/cgi/generic3/erbitux.htm
Erbitux (ImClone Systems Inc) fda sheet
Erbitux (ImClone Systems Inc) msds (material safety sheet)
Erbitux (ImClone Systems Inc) Synthesis Reference
sequence listed in Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.) patent 6,217,866
Erbitux (ImClone Systems Inc) Molecular Weight
145781.6
Erbitux (ImClone Systems Inc) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Erbitux (ImClone Systems Inc) H2O Solubility
No information avaliable
Erbitux (ImClone Systems Inc) State
Liquid
Erbitux (ImClone Systems Inc) LogP
-0.413
Erbitux (ImClone Systems Inc) Dosage Forms
Solution (IV Infusion)
Erbitux (ImClone Systems Inc) Indication
For treatment of metastatic colorectal cancer
Erbitux (ImClone Systems Inc) Pharmacology
Used in the treatment of colorectal cancer, Erbitux binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Erbitux competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor??“alpha. Binding of Erbitux to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.
Erbitux (ImClone Systems Inc) Absorption
No information avaliable
Erbitux (ImClone Systems Inc) side effects and Toxicity
No information avaliable
Erbitux (ImClone Systems Inc) Patient Information
No information avaliable
Erbitux (ImClone Systems Inc) Organisms Affected
Humans and other mammals
